Please try another search
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Name | Age | Since | Title |
---|---|---|---|
Quan Dong Nguyen | - | 2021 | Member of the Scientific Advisory Board |
Adrian Vella | - | 2021 | Member of the Scientific Advisory Board |
Gilbert M. Labrucherie | 51 | 2019 | Independent Director |
Alvin Schmaier | - | - | Member of the Scientific Advisory Board |
Nevan Charles Elam | 57 | 2013 | Founder, CEO & Acting Chairman of the Board |
Jerrold M. Olefsky | - | 2014 | Member of the Scientific Advisory Board |
Robert B. Bhisitkul | - | - | Member of the Scientific Advisory Board |
Nerissa C. Kreher | 50 | 2021 | Independent Director |
Young-Jin Kim | 68 | 2019 | Director |
Philippe Fauchet | 67 | 2020 | Independent Director |
Wladimir Hogenhuis | 58 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review